Functional Analysis of the Validamycin Biosynthetic Gene Cluster and Engineered Production of Validoxylamine A  by Bai, Linquan et al.
Chemistry & Biology 13, 387–397, April 2006 ª2006 Elsevier Ltd All rights reserved DOI 10.1016/j.chembiol.2006.02.002Functional Analysis of the Validamycin
Biosynthetic Gene Cluster and Engineered
Production of Validoxylamine ALinquan Bai,1 Lei Li,1,4 Hui Xu,1,4
Kazuyuki Minagawa,2,4 Yi Yu,1 Yirong Zhang,1
Xiufen Zhou,1 Heinz G. Floss,3 Taifo Mahmud,2,*
and Zixin Deng1,*
1Laboratory of Microbial Metabolism and School
of Life Science & Biotechnology
Shanghai Jiaotong University
Shanghai 200030
China
2Department of Pharmaceutical Sciences
Oregon State University
Corvallis, Oregon 97331
3Department of Chemistry
University of Washington
Seattle, Washington 98195
Summary
A 45 kb DNA sequencing analysis from Streptomyces
hygroscopicus 5008 involved in validamycin A (VAL-
A) biosynthesis revealed 16 structural genes, 2 regula-
tory genes, 5 genes related transport, transposition/in-
tegration or tellurium resistance; another 4 genes had
no obvious identity. The VAL-A biosynthetic pathway
was proposed, with assignment of the required ge-
netic functions confined to the sequenced region. A
cluster of eight reassembled genes was found to sup-
port VAL-A synthesis in a heterologous host, S. livid-
ans 1326. In vivo inactivation of the putative glycosyl-
transferase gene (valG) abolished the final attachment
of glucose for VAL production and resulted in accu-
mulation of the VAL-A precursor, validoxylamine,
while the normal production of VAL-A could be re-
stored by complementation with valG. The role of
valG in the glycosylation of validoxylamine to VAL-A
was demonstrated in vitro by enzymatic assay.
Introduction
Validamycin A (VAL-A; Figure 1A), a weakly basic C7N-
aminocyclitol-containing antibiotic, was first isolated
from Streptomyces hygroscopicus var. limoneus, and
later from S. hygroscopicus var. jinganggensis 5008
(hereafter S. hygroscopicus 5008 or strain 5008). It is
widely used, especially in Asia, to control sheath blight
disease of rice plants and dumping-off of cucumber
seedlings caused by the fungus Pellicularia sasakii
(Rhizoctonia solani) [1]. In the presence of VAL-A, nor-
mal extension of the main fungal hyphae is switched to
an abnormal branching at the tips, and further develop-
ment of those growing fungi is repressed [2]. VAL-A was
also found to have insecticidal activity, most likely
resulting from its strong inhibition of trehalase, the
trehalose-degrading enzyme. Trehalose is a primary
storage carbohydrate in fungi (8%–10% of the dry cell
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4 These authors contributed equally to this work.weight ofP. sasakii) and is recognized as a characteristic
blood sugar of insects. The enzyme trehalase appears to
play an important metabolic role in these organisms in
generating glucose for energy supply or for other phys-
iological purposes. Its inhibition results in disruption of
the glucose supply system of the fungus, leading to
growth abnormality and death. Although in vitro experi-
ments revealed that the pseudodisaccharide, validoxyl-
amine A, is more active than VAL-A against trehalase [3],
results of in vivo experiments suggest the opposite. It is
proposed that the presence of the glucose moiety on
VAL-A is essential for its efficient entry into fungal myce-
lia, in which it is hydrolyzed by an a-glucosidase to yield
the active pharmacophore, validoxylamine A [4]. VAL-A
is also used as the source of valienamine, a pharma-
ceutically important precursor for the production of the
antidiabetic drug, Voglibose (Basen), whose mechanism
of action is to inhibit a-glucosidase in the intestine, com-
parable to another antidiabetic agent, acarbose.
The biosynthesis of the C7N-aminocyclitol moiety has
been investigated to some extent in Actinoplanes sp.
SE50/110 (acarbose-producer) [5–7], in S. hygroscopi-
cus var. limoneus (VAL-A producer) [8–10], and, more
recently, in Microtetraspora spiralis (pyralomicin pro-
ducer) [11]. Feeding experiments with a number of
isotopically labeled potential intermediates to S. hygro-
scopicus var. limoneus [8, 10, 12] demonstrated that
2-epi-5-epi-valiolone, 5-epi-valiolone, valienone, and
validone were incorporated into VAL-A, leading to a pro-
posed biosynthetic pathway to VAL-A, as shown in
Figure 1B. Similar feeding experiments were also per-
formed with Actinoplanes sp. SE50/110 [6, 7] and Micro-
tetraspora spiralis, but with surprisingly different in-
corporation patterns. Only 2-epi-5-epi-valiolone and
5-epi-valiolone were found to be efficiently incorporated
into pyralomicin [11], whereas 2-epi-5-epi-valiolone was
the only one of these compounds incorporated into
acarbose.
The gene cluster for acarbose biosynthesis has been
cloned and a number of the proteins involved have
been characterized, resulting in a proposed biosynthetic
pathway to acarbose [13]. The pathway is initiated by
a cyclization of sedoheptulose 7-phosphate, a C7 sugar
phosphate involved in the pentose phosphate pathway,
catalyzed by the dehydroquinate synthase-like protein,
AcbC, to give 2-epi-5-epi-valiolone (Figure 1B) [5]. The
latter compound is then phosphorylated to its 7-phos-
phate derivative catalyzed by the kinase AcbM. Further-
more, the product of acbO, which was found in the same
operon as acbC and acbM, was identified as a 2-epi-
5-epi-valiolone 7-phosphate 2-epimerase [14]. Efficient
incorporation of 2-epi-5-epi-valiolone into both VAL
and acarbose strongly suggested that both biosynthetic
pathways share the same cyclization step. However, fur-
ther downstream the pathways to the two compounds
may be different, as feeding experiments with the pro-
ducing strains gave two different patterns. This leaves
many open questions surrounding the biosynthesis of
acarbose and VAL-A, which cannot be addressed by
conventional feeding experiments alone.
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cyclitols and Proposed Biosynthetic Pathways
to VAL-A and Acarbose
(Top) Chemical structures of VAL-A, acar-
bose, and pyralomicin 1a. Dashed-boxed re-
gions show the cyclitol moiety shared by all
three compounds.
(Bottom) Previously proposed biosynthetic
pathways to VAL-A [8] and acarbose [13, 14].Using the acbC gene from the acarbose cluster as
a heterologous probe, we have successfully cloned
and identified the VAL-A biosynthetic genes from a ge-
nomic library of S. hygroscopicus 5008. Sequencing of
a 6 kb BamHI fragment (Figure 2A), in vivo gene inactiva-
tion, and in vitro biochemical characterization resulted
in the identification of 2-epi-5-epi-valiolone synthase
(ValA), a homolog of AcbC, paving the way for further
sequencing of the entire cluster [15].Here we describe the sequencing and functional anal-
ysis of 45 kb of DNA, which led to the identification of
8 out of 27 genes as essential for validamycin biosynthe-
sis through reconstituted heterologous gene expression
in S. lividans 1326. We also demonstrate the glycosyl-
transferase function of the identified valG gene, first by
its in vivo inactivation and functional complementation
in strain 5008, second by in vitro enzymatic character-
ization of the ValG protein expressed in EscherichiaFigure 2. Cloning Strategy for Sequencing and Genetic Organization of val Gene Cluster
(A) Cloning strategy for sequencing of the 45 kb region. B, BamHI; C, ClaI; E, EcoRI.
(B) Genetic organization of the val gene cluster. Genes proposed to be involved in validamycin biosynthesis are represented as black arrows.
The previously sequenced 6.0 kb BamHI fragment was indicated by double-arrowed line.
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389Table 1. Deduced Functions of the Open Reading Frames in the val Gene Cluster
Protein aa Proposed Function Homologs, Origin
Identity,
Similarity
(%)
Accession
No.
ORF1 400 Integrase Urd-Int, Streptomyces fradiae 88, 94 AAF00216
ORF2 391 Transposase SAV1204, Streptomyces avermitilis 90, 92 BAC68914
ORF3 276 Transposase SCO7080, Streptomyces ceolicolor 91, 93 CAB89752
ValO 221 Phosphatase/phosphohexomutase COG0637, Thermobifida fusca 39, 58 ZP_00293893
ValN 331 Cyclitol reductase Glr0369, Gloeobacter violaceus 29, 39 BAC88310
ValM 424 Aminotransferase DRA0029, Deinococcus radiodurans 39, 54 NP_285353
ValL 492 Validoxylamine A 70-phosphate synthase Rxy102001033, Rubrobacter xylanophilus 30, 47 ZP_00187712
ValK 324 Epimerase/dehydratase APE1179, Aeropyrum pernix 31, 51 BAA80165
ValA 414 2-epi-5-epi-valiolone synthasea AcbCa, Actinoplanes sp. 50/110 48, 65 CAA77208
ValB 373 Valienol-1-phosphate nucleotidylyltransferase GlgC, Bacillus halodurans 33, 50 BAB04806
ValC 351 Cyclitol kinase GlcK, Bacillus cereus 29, 44 ZP_00238533
ValD 451 Glyoxalase NocaDRAFT_3188, Nocardioides sp. JS614 40, 49 ZP_00657213
ValE 331 Oxidoreductase SAV4805, S. avermitilis 45, 56 BAC72517
ValF 401 Oxidoreductase SAV1825, S. avermitilis 80, 87 BAC69536
ValG 422 Glycosyltransferasea KfoCa, Escherichia coli 35, 49 BAC00523
ValH 398 Transport protein SAV6900, S. avermitilis 52, 66 BAC74611
ValI 611 Glycosyl hydrolase SAV6503, S. avermitilis 69, 81 BAC74214
ValJ 305 Oxidoreductase SAV4805, S. avermitilis 43, 55 BAC72517
ORF4 204 Unknown Mll4476, Mesorhizobium loti 39, 55 NP_105339
ORF5 347 Unknown SMc00549, Sinorhizobium meliloti 28, 47 NP_385900
ValP 293 Regulatory protein SCO3723, S. coelicolor 49, 63 CAD55330
ValQ 163 Regulatory protein SCO3723, S. coelicolor 45, 59 CAD55330
ORF6 191 Tellurium resistance protein SAV896, S. avermitilis 92, 97 BAC68606
ORF7 451 Unknown SCO3725, S. coelicolor 72, 81 CAB76972
ORF8 290 Unknown SAV7268, S. avermitilis 52, 68 BAC74979
ORF9 308 Esterase Bcepa03001004, Burkholderia cepacia 47, 59 ZP_00218391
ORF10 349 Cytochrome P450 hydroxylase P450-SU2, Streptomyces griseolus 51, 61 AAA26825
a With confirmed function.coli, and third by heterologous expression of the val
gene cluster, with or without valG, to yield VAL-A and
validoxylamine A, respectively, in S. lividans 1326.
Results
Overall Architecture of the Sequenced Region
A total of 45,168 bp of DNA sequence (deposited in Gen-
Bank under accession number DQ164098), including the
previously reported 5877 bp of DNA (AY753181), was
determined using overlapping or linking fragments (Fig-
ure 2A). Overall GC content of this region is 68.7%—
somewhat lower than the typical GC content as exempli-
fied by S. coelicolor A3(2) [16] and S. avermitilis [17]
(w72%). In silico analysis of the sequence revealed the
presence of 27 complete open reading frames (ORFs),
whose organization is shown in Figure 2B and proposed
functions are listed in Table 1. Structural and regulatory
genes likely involved in VAL-A biosynthesis, designated
as valA-Q and indicated as black arrows in Figure 2B,
are distributed in the middle part of the sequenced re-
gion, among which subcluster valA-valJ and valK-valN
seem to be transcribed in opposite directions.
The valA-valJ Subcluster
valA, whose deduced protein sequence shows signifi-
cant homology to AcbC from the acarbose biosynthetic
gene cluster, was confirmed to encode ValA [15]. The
deduced amino acid sequence of ValB shows 33% iden-
tity with GlgC, a glucose-1-phosphate adenylyltransfer-
ase from Bacillus halodurans C-125 [18]. ValC shows
30% identity with AcbM, the 2-epi-5-epi-valiolone7-kinase from the acarbose cluster, whose demon-
strated function is to phosphorylate 2-epi-5-epi-valio-
lone to form 2-epi-5-epi-valiolone 7-phosphate [19].
Additionally, ValC shows a weaker homology to gluco-
kinase from a Bacillus species (29% identity/44%
similarity).
Full-length ValD (451 aa) is homologous to a putative
glyoxalase/bleomycin resistance protein/dioxygenase
domain from Nocardioides sp. JS614. Two domains of
ValD, one at Gly35-Glu194 and the other at Gly220-
Ala382, showed 35.5% identity/50% similarity to each
other.
Both ValE (331 aa) and ValJ (305 aa) show homology
to 2-oxoglutarate and Fe(II)-dependent oxygenases,
whose enzymatic functions are known to catalyze a vari-
ety of reactions typically involving the oxidation of an
organic substrate with an oxygen molecule, such as hy-
droxylation, desaturation, or oxidative ring closure [20].
Noticeably, ValE and ValJ showed significant homology
(79.8% identity at nucleotide [nt] level and 66.3% iden-
tity at the protein level), and mainly differed from each
other at the C terminus.
ValF is highly homologous with putative oxidoreduc-
tases from S. avermitilis and S. coelicolor (76% iden-
tity/82% similarity). In addition, a ValF-related glucose-
fructose oxidoreductase from Zymomonas mobilis is
known to catalyze the reductive conversion of fructose
to sorbitol [21], suggesting that ValF might be involved
in the keto reduction of intermediate compounds in
VAL-A biosynthesis.
ValG exhibits considerable homology to chondroitin
polymerase KfoC from E. coli K4, which is known to
Chemistry & Biology
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in the assembly of capsule polysaccharide K4 antigen
[22]. However, ValG (422 aa) is 264 aa shorter than
KfoC (686 aa), but 250 aa residues of its N-terminal do-
main, which is required for sugar donor binding, are
very similar to known glycosyltransferases. In addition,
one conserved short motif of DGS and two DXD motifs,
which have been proposed to facilitate NDP-sugar bind-
ing and Mn2+ ion binding [23], respectively, are present
in ValG.
The deduced product of valH is homologous to puta-
tive transport protein SAV6900 from S. avermitilis and
the fucose permease FucP from Mesorhizobium sp.
BNC1 (33% identity and 50% similarity), whose func-
tions are known to be cotransport of fucose, glucose,
or galactose with H+ [24]. Analysis of ValH by using the
TMHMM Server v. 2.0 [25] suggests that 11 transmem-
brane helices span the length of the protein.
ValI seems to be closely related to the putative glu-
coamylase SAV6503 from S. avermitilis, which belongs
to the glycosyl hydrolase family 15 [26]. Glucoamylases
are known to catalyze the hydrolysis of a-1,4 and a-1,6
glucosidic linkages to release b-D-glucose from the
nonreducing ends of starch and related poly- and oligo-
saccharides [27]. However, no obvious function could
be assigned in the pathway for VAL-A biosynthesis, ex-
cept that D-glucose could be a precursor for VAL-A.
The valK-valN Subcluster
The valK-valN genes are predicted to be transcribed in
the opposite direction to the valA-valJ genes. BLAST
analysis of ValK showed significant homology with
dTDP-4-dehydrorhamnose reductase (RmlD) from
Aeropyrum pernix, a member of the reductase/epimer-
ase/dehydrogenase/dehydratase protein superfamily
putatively involved in the biosynthesis of L-rhamnose
from glucose-1-phosphate [28]. ValK contains a strictly
conserved (P-X3-Y-X3-K-X3-E) motif that is characteris-
tic for this superfamily and another conserved (STDNVF)
motif that is unique for RmlD-type proteins [29]. Interest-
ingly, the conserved NAD(P) binding Wierenga motif
(G-X2-G-X2-G) [30] is missing from the N terminus of
ValK. NAD(P)+-independent sugar epimerases from
E. coli and other microorganisms have been reported
previously [29, 31]. The reaction mechanism involves
substrate to metal binding and a cis enediolate-
stabilized intermediate [32, 33]. However, no significant
sequence similarity was found between ValK and the
NAD(P)+-independent sugar epimerases.
ValL shows significant homology to the putative treha-
lose 6-phosphate synthase Rxyl021033 from Rubro-
bacter xylanophilus and lower homology to its counter-
part OtsA in E. coli. In E. coli, the trehalose 6-phosphate
synthase (OtsA) and the trehalose 6-phosphatase (OtsB)
are responsible for the biosynthesis of trehalose from
glucose-6-phosphate and UDP-glucose, with net reten-
tion of the anomeric configuration of the donor sugar
[28].
ValM is closely related to pyridoxal 50-phosphate-
dependent (PLP) aminotransferases, such as the putative
4-aminobutyrate aminotransferase from Deinococcus
radiodurans and the acetylornithine aminotransferase
from Methanosarcina mazei. Consistent with other ami-
notransferases, the conserved Lys268 of ValM is be-lieved to be the PLP binding residue for the Schiff
base linkage. In addition, other conserved residues im-
portant for PLP binding (Asp239, Gln242, and Thr322)
and catalysis (Glu206 and Arg349) are also present [34].
ValN shows significant homology to the zinc-depen-
dent threonine dehydrogenase, Krad06004313, from
Kineococcus radiotolerans and AcbL from the acarbose
pathway of Actinoplanes sp. SE50/110 (29% identity/
39% similarity). AcbL, a putative cyclitol dehydrogenase
was proposed to be involved in the reduction of the C-1
keto group of valienone 7-phosphate to give 1-epi-valie-
nol 7-phosphate [19].
Putative Regulatory Genes
ValP and valQ are predicted to encode a two-compo-
nent regulatory system consisting of a separate histidine
kinase (sensor) and a Sigma B PP2C-like phosphatase
(response regulator) [35], as ValP showed the highest
homology with the response regulator phosphatase
domain and ValQ with the sensor kinase domain of
SCO3723 from S. coelicolor A3(2). The existence of
valP and valQ as two independent genes separated by
only 28 bp seems unique in the val gene cluster, since
most of the counterpart proteins, exemplified by
SCO3723, are known to exist as single peptide with
two domains conforming to ValP and ValQ, respectively.
It is not known yet whether the independent organiza-
tion of ValP and ValQ could have anything to do with
the induction of Sigma B activity and subsequent valida-
mycin production in response to environmental stress,
such as increased temperature and/or high salt concen-
tration. However, we have consistently observed an
apparent increase in production of VAL-A and enhanced
transcriptions of both valP and valQ in parallel when the
producer was grown at 37ºC rather than at 30ºC (Lei Li
and Linquan Bai, unpublished data).
Boundaries of the Cluster and Other Most Likely
Unrelated Genes
Beyond valN, three transposase-like or integrase-like
ORFs (ORF1–3) and valO, which exhibits homology to
a predicted phosphatase/phosphohexomutase from
Thermobifida fusca, were detected. To determine the
left boundary of the biosynthetic gene cluster, valO,
which is located 764 bp downstream of valN and most
likely monocistronically transcribed, was inactivated.
Through double crossover recombination mediated by
the 2.5 kb left flanking sequence and 4.0 kb right flanking
sequence, an internal 588 bp fragment was replaced by
aac(3)IV via ReDirect methodology [36]. The mutant
ZYR-5, confirmed by PCR amplification, was found to
produce a comparable amount of VAL-A as the wild-
type, suggesting that valO is not involved in the biosyn-
thesis of VAL-A. Thus, the left-border of the val gene
cluster was defined.
Of the seven ORFs flanking the putative two-compo-
nent regulatory genes, valP and valQ, ORF 4, 5, 7, and
8 seem to encode proteins with unknown biological
functions. Moreover, none of the detected homologies
of ORF 6, 9, and 10, with a tellurium resistance protein,
a group of esterases, and a cytochrome P450, seem to
be relevant to validamycin biosynthesis. It is thus likely
that all of the genes required for VAL-A biosynthesis
Validamycin Biosynthetic Gene Cluster
391Figure 3. Heterologous Production of Validoxylamine A and VAL-A
(A) Reassembly of valABCKLMN and MS analysis (MS1). PermE*, the upmutated promoter of the erythromycin resistance gene; E, EcoRI. Frag-
mentation of validoxylamine A (m/z 336.1) yields validamine (m/z 178.1) (MS2).
(B) Coexpression of valABCKLMN and valG and MS detection (MS1). Fragmentation of VAL-A (m/z 498.2) generates validoxylamine A (m/z
336.1) and validamine (m/z 178.1) (MS2).are located between valN and valQ in a w30 kb region
(Figure 2B).
Heterologous Production of Validoxylamine A
and VAL-A in S. lividans 1326
valABC seems to transcribe as one operon and
valKLMN as another operon transcribed in the opposite
direction (Figure 2B). The two operons were reas-
sembled to have seven genes in the same orientation
under the control of a constitutive PermE* promoter
(Figure 3A), and a construct (pJTU757) was introduced
into a heterologous host, S. lividans 1326, to see if the
biosynthetic intermediate, validoxylamine A, can be pro-
duced. Since the 251 bp fragment to the N terminus of
valK may still contain its own promoter, the recombi-
nant, XH-6, was thus initially fermented at 37ºC instead
of at 30ºC, as commonly set for S. lividans.
Even though bioassay with chloroform-extracted fer-
mentation broth of XH-6 showed almost no inhibitory
activity against P. sasakii, and HPLC analysis gave no
obvious peak corresponding to validoxylamine A be-
cause of the lower yield, mass spectrometry analysis
through direct injection of the sample did reveal the
presence of validoxylamine A (Figure 3A). The typical
fragmentation of validoxylamine A (m/z 336.1) underpositive-ion mode gives validamine (m/z 178.1). The iso-
lated compound with m/z of 336.3 (MS1) from XH-6 was
indeed fragmented to give a peak with m/z of 178.1 (Fig-
ure 3A, MS2). These data demonstrate that only seven
genes, valABCKLMN, from the two original operons
are required for the synthesis of validoxylamine A. Fer-
mentation of XH-6 at 30ºC, followed by MS analysis,
also revealed the production of validoxylamine A at
low yield (data not shown).
Since valG is the only gene found in the sequenced re-
gion encoding a glycosyltransferase, it was tempting to
coexpress this gene with valABCKLMN for the possible
production of VAL-A in S. lividans. The new recombinant
XH-9 harboring valABCKLMNG showed inhibitory activ-
ity in bioassay after fermentation at 37ºC for 7 days, or at
30ºC for 11 days (data not shown), suggesting the accu-
mulation of VAL-A. The typical fragmentation pattern of
VAL-A (m/z 498.2) under positive-ion mode is the loss of
glucose, to give validoxylamine A (m/z 336.1), which is
further fragmented to validamine (m/z 178.1). Detailed
analysis by mass spectrometry of a 7-day fermented
broth of XH-9 at 37ºC clearly indicated the presence of
VAL-A with m/z of 498.2, which was sequentially frag-
mented into validoxylamine A (m/z 336.1) and valida-
mine (m/z 178.1) in the MS/MS experiment (Figure 3B).
Chemistry & Biology
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(A) Schematic representation of the replacement of an 806 bp internal fragment of valG with the 1.4 kb aac(3)IV. In shuttle plasmid pJTU609,
aac(3)IV was inserted between the 2.4 kb and 1.0 kb genomic fragments originally flanking the deleted 806 bp region. While wild-type S. hygro-
scopicus should give a 2.1 kb PCR-amplified product, mutant LL-1 should yield a 1.5 kb product by using a pair of primers, ValG2-F and
ValG2-R.
(B) PCR analysis of wild-type S. hygroscopicus and mutant LL-1.
(C) Bioassay comparison between the wild-type (left), LL-1 (middle), and LL-101 (right). LL-101 is the derivative of LL-1 harboring shuttle plas-
mid pJTU612 with valG.
(D) HPLC profiles of the standards, wild-type, LL-1, and LL-101. The retention time of VAL-A is 9.7 min, and that of validoxylamine A is 6.5 min.The 11 day fermentation broth of XH-9 at 30ºC was also
analyzed by MS/MS, and an obviously similar fragmen-
tation pattern for VAL-A could be observed (data not
shown).
The successful heterologous production of validoxyl-
amine A and VAL-A inS. lividans 1326 not only confirmed
the necessity for VAL-A biosynthesis of the 8 structural
genes from the 27 ORFs found in the sequenced region,
but also revealed the identity of valG as a glycosyltrans-
ferase that transfers activated glucose to validoxyl-
amine A as the final step in VAL-A biosynthesis.
Targeted Replacement of valG Abolishes
VAL-A Biosynthesis
LL-1 (Figure 4B) was one of the confirmed mutants, with
an internal 806 bp region of valG (from nt number 112 to
918) replaced by an aac(3)IV from the strain 5008 (Fig-
ure 4A). Bioassay indicated that the LL-1 fermentation
broth had retained inhibitory activity, albeit at a reduced
capacity (Figure 4C), but the presence of VAL-A (reten-
tion time of 9.7 min) could not be detected by HPLC
analysis. Despite the fact that, under normal conditions,the wild-type strains also produced validoxylamine A
(retention time of 6.5 min), a significantly increased ac-
cumulation of validoxylamine A was observed in LL-1
(Figure 4D). The abolished production of VAL-A and
the increased accumulation of validoxylamine A in
LL-1 strongly suggest that ValG catalyzes the glycosyla-
tion of validoxylamine A to yield VAL-A. The observed
weak inhibitory activity agrees with the previous finding
that validoxylamine A has much lower in vivo inhibitory
activity than VAL-A [4].
Complementation by Cloned valG Restores
VAL-A Production
When pJTU612, a pIJ101-derived plasmid with an intact
valG, was introduced into mutant LL-1, the culture broth
of the thiostrepton-resistant exconjugant (LL-101) was
found to have regained the inhibitory activity (Figure 4C)
in bioassay. HPLC analysis unambiguously demon-
strated the presence of VAL-A with the retention time
of 9.7 min. However, the presence of valG under the
strong constitutively expressed PermE* promoter in
LL-101 was not sufficient for the conversion of all
Validamycin Biosynthetic Gene Cluster
393Figure 5. Heterologous Expression of valG
and Characterization of the Glycosyltransfer-
ase
(A) SDS-PAGE analysis of ValG protein: (1)
molecular weight marker; (2) soluble protein
of extract of E. coli BL21Gold(DE3)pLysS/
valG before induction; (3) total protein of
extract of E. coli BL21Gold(DE3)pLysS/valG
after induction with IPTG; (4) soluble protein
of line 3; (5) purified his-tagged ValG.
(B) TLC analysis of ValG reaction (silica gel,
solvent system: nPrOH:AcOH:H2O = 4:1:1);
R, validoxylamine A standard; U, ValG re-
action by using UDP-glucose as glucosyl do-
nor, G, ValG reaction by using GDP-glucose
as glucosyl donor; A, ValG reaction by using
ADP-glucose as glucosyl donor; T, ValG re-
action using TDP-glucose as glucosyl donor.
(C) Conversion scheme of validoxylamine A
to VAL-A catalyzed by ValG.validoxylamine A to VAL-A, as a peak with the retention
time of 6.5 min corresponding to validoxylamine A was
also observed (Figure 4D).
In Vitro Glycosylation of Validoxylamine A
to VAL-A Using Recombinant ValG
Further proof to support the glycosyltransferase func-
tion of valG was obtained from its heterologous ex-
pression in E. coli, which gave rise to a 49 kDa soluble
polyhistidine-tagged protein. Affinity purification on an
Ni-NTA spin column (QIAGEN) or a BD TALON column
gave a protein that was >75% pure as judged by SDS-
polyacrylamide gel electrophoresis (Figure 5A). To test
the catalytic activity of ValG, the enzymatic reaction
was carried out using validoxylamine A and UDP-,
GDP-, ADP-, or TDP-glucose as substrates. The reac-
tions gave rise to a product that has the same Rf value
as authentic VAL-A on TLC (Figure 5B). On the other
hand, incubation with cell-free extracts of E. coli harbor-
ing empty pRSET-B vector gave no product (data not
shown). The product was confirmed to be VAL-A by
ESI-MS and NMR. UDP-glucose was the most efficient
glycosyl donor for the ValG reaction, as judged by TLC
(Figure 5B), whereas GDP-glucose was less efficient
and ADP-glucose was much less efficient. To our sur-
prise, TDP-glucose was the least efficient donor for
the reaction among the activated sugars tested.
Discussion
Earlier feeding experiments with isotopically labeled
potential intermediates led to a proposal that the bio-
synthesis of VAL-A is initiated by the cyclization of
D-sedoheptulose 7-phosphate to form 2-epi-5-epi-
valiolone, which subsequently epimerizes at C-2 to
give 5-epi-valiolone, followed by dehydration between
C-5 and C-6 to generate valienone. The conversion of
valienone to validone takes place by anti-addition of hy-
drogen followed by transamination, with the a-nitrogen
of glutamate as the probable nitrogen source, to form
validamine. Analysis of anw45 kb region of theS. hygro-
scopicus 5008 chromosome revealed 16 potential struc-tural genes, which include genes deduced or proven to
encode ValA, epimerase/dehydratase (ValK), reductase
(ValN), transaminase (ValM), and glycosyltransferase
(ValG) (Table1). These enzymes fit nicely with the pro-
posed scheme of VAL-A biosynthesis resulting from
the feeding experiments. Despite some discrepancies
between the biosynthesis of acarbose and VAL-A,
cloning of the acarbose biosynthetic gene cluster and
subsequent biochemical characterization of several
enzymes involved in the biosynthesis has provided
additional information for the elucidation of VAL-A bio-
synthesis [13]. In the case of acarbose, 2-epi-5-epi-
valiolone, the cyclization product of AcbC is phosphor-
ylated by the kinase AcbM to give 2-epi-5-epi-valiolone
7-phosphate. Further conversion to 5-epi-valiolone 7-
phosphate is catalyzed by the epimerase AcbO. The
presence of ValC, a homolog of AcbM, in the val gene
cluster suggests the involvement of phosphorylated in-
termediates in VAL-A biosynthesis as well. However,
since 2-epi-5-epi-valiolone, 5-epi-valiolone, valienone,
and validone were efficiently incorporated into VAL-A,
the kinase (ValC) may utilize valienone and/or validone
as substrate. Alternatively, the kinase might have broad
substrate specificity, activating 2-epi-5-epi-valiolone,
5-epi-valiolone, valienone, and validone, and making it
possible for them to be incorporated into the biosyn-
thetic pathway.
In analogy to the proposed function of the dehydroge-
nase AcbL in acarbose biosynthesis, ValN is predicted
to reduce the C-1 keto group of valienone-7-phosphate
to give either valienol 7-phosphate or its epimer, 1-epi-
valienol 7-phosphate (Figure 6). If valienol 7-phosphate
is formed, a downstream coupling reaction, most likely
catalyzed by the trehalose 6-phosphate synthase homo-
log (ValL), would occur with net retention of the C-1 con-
figuration of the unsaturated cyclitol. However, if 1-epi-
valienol 7-phosphate is formed, the coupling reaction
must take place with inversion of the C-1 configuration.
In acarbose biosynthesis, it was proposed that reduc-
tion of valienone 7-phosphate yields 1-epi-valienol 7-
phosphate, and further phosphorylation of the latter
compound by an unidentified kinase gives 1-epi-valienol
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tractive, there is no evidence for the presence of a sec-
ond kinase in the validamycin cluster. The presence of
valO, which encodes a protein homologous to phospha-
tase/phosphohexomutase, in the validamycin cluster
conversely suggests the involvement of a phosphomu-
tation step from the C-7 to the C-1 hydroxyl group, as
commonly observed in sugar biosyntheses. However,
inactivation of valO did not abolish the production of
VAL-A, which leaves this part of the pathway unclear.
Nevertheless, the availability of the genetic informa-
tion reported here, as well as results from our previous
feeding experiments and biochemical analysis of several
related enzymes, allows us to propose a more compre-
hensive pathway to VAL-A (Figure 6). In vivo inactivation
and in vitro characterization of ValA confirmed the initia-
tion step from D-sedoheptulose 7-phosphate to the cy-
clic product, 2-epi-5-epi-valionone [15]. Subsequently,
epimerization at C-2 and dehydration at C-5/C-6 of 2-
epi-5-epi-valionone by the proposed bifunctional ValK
would give valienone. ValK has significant homology
with the sugar epimerase/dehydratase, and it appears
to be the only plausible candidate enzyme for the epime-
rization and dehydration reactions among the eight pro-
teins known to be involved in VAL-A biosynthesis. In ad-
dition, ValK may not require NAD(P)+ for catalytic activity,
which is similar to the L-ribulose-5-phosphate 4-epimer-
ase and the dTDP-4-dehydrorhamnose 3,5-epimerase
[29, 31]. However, no significant homology was found
between the primary structures of ValK and the NAD+-
independent sugar epimerases. This raises questions
regarding the function and reaction mechanism of
ValK, which prompts further investigations.
Prior to any further processing, valienone may be
phosphorylated, presumably by the kinase, ValC, to
give valienone 7-phosphate. Valienone 7-phosphate
may serve as the branching point to be reduced to val-idone 7-phosphate on the one hand, and to valienol
7-phosphate or 1-epi-valienol 7-phosphate on the
other, by the reductase ValN and/or other reductases/
dehydrogenases. There are three oxidoreductase genes
present in the cluster: valE, valF, and valJ. However, the
results of the heterologous expression experiments in
S. lividans suggest that these genes are not necessary
for the biosynthesis of VAL-A. Even so, it may be that
they are involved in the biosynthesis of validamycins B
and/or G, the hydroxylated analogs of VAL-A. Trans-
amination of the keto group of validone 7-phosphate
catalyzed by the aminotransferase ValM would give
validamine 7-phosphate. On the other hand, valienol
7-phosphate or its 1-epimer is either phosphorylated
at C-1 by an unidentified kinase to generate the 1,7-
diphosphate derivative or transformed into valienol
1-phosphate through catalysis by a phosphogluco-
mutase. The product is subsequently converted to an
NDP-valienol derivative by the nucleotidyl transferase
ValB. Condensation of validamine 7-phosphate with
the NDP-valienol derivative would give phosphorylated
validoxylamine A, whose conversion to validoxylamine
A requires a dephosphorylation activity. The correspond-
ing phosphatase has not been located in the sequenced
region. However, an internal trehalose 7-phosphate
phosphatase or a nonspecific sugar phosphatase may
be able to carry out this hydrolytic reaction. Finally,
validoxylamine A is converted to VAL-A biosynthesis
through catalysis by the glycosyltransferase ValG by us-
ing UDP-glucose as the sugar donor.
Significance
VAL-A is a strong crop protectant produced by Strep-
tomyces hygroscopicus and is widely used for the
treatment of the sheath blight disease of rice plants
and the vegetable dumping-off caused by the fungus
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uct, valienamine, is a pharmaceutically important pre-
cursor for the production of the antidiabetic agent,
voglibose. Despite its significant and wide applica-
tions in the biomedical and agricultural sectors, little
is known about its biosynthesis. Sequencing and bio-
informatics analysis of the validamycin biosynthetic
gene cluster, as well as in vivo and in vitro character-
ization of a number of enzymes involved in VAL-A bio-
synthesis, provide important insights into the bio-
synthesis of this antibiotic. The data presented will
also aid in the elucidation of the biosynthesis of other
related aminocyclitol-containing natural products. In
combination with knowledge about the acarbose bio-
synthetic gene cluster, it may now be possible to de-
sign unique primers for the screening and cloning of
other aminocyclitol biosynthetic gene clusters from
various sources. Exemplified by the significant accu-
mulation of validoxylamine A in the glycosyltransfer-
asemutants, in-depth knowledge about VAL-A biosyn-
thesis could potentially be used to establish a platform
for the production of drug precursors (e.g., valien-
amine, validamine, valiolamine, and hydroxyvalid-
amine). Functional analysis of validamycin biosynthe-
sis also sets the stage for creating novel analogs of
VAL-A via combinatorial biosynthesis and yield im-
provement through metabolic engineering. Finally,
with all the genes necessary for the synthesis of this
important crop protectant at hand, one can contem-
plate the possibility of expressing them in plant sys-
tems to endow crop plants with their built-in protec-
tion against pathogens such as P. sasakii.
Experimental Procedures
Bacterial Strains, Plasmids, Culture Techniques, and Media
S. hygroscopicus 5008 [37] and its derivatives were grown either on
solid SFM medium or in modified liquid TSB medium [38] (supple-
mented with 1% yeast extract and 10.3% sucrose). Fermentation
was carried out in FM-II medium at 37ºC for 6 days [15]. DH10B
(GIBCO-BRL), ET12567(pUZ8002) [39], and BL21Gold(DE3)pLysS
[40] were used as E. coli hosts for plasmid construction, E. coli-
Streptomyces conjugation, and protein overexpression, respec-
tively. P. sasakii was used as indicator strain for VAL-A bioassay.
pHZ1358 was the cosmid vector used for constructing the 5008
genomic library and for gene inactivation [41]. pJTU472 contains
aac(3)IV with HindIII sites on both sides, which was originally cloned
from pHZ1070 [42]. pIJ2925 [43] was E. coli vector for plasmid con-
struction and pUC18 [44] was E. coli vector for DNA sequencing.
pRSET-B (Invitrogen) was used as vector for protein overexpression
in E. coli.
Shuttle vector pJTU695 for our complementation study was con-
structed as follows. The 1628 bp region between SphI and NruI of the
pET15b (Novagen) was replaced first by an 868 bp SphI-BalI frag-
ment containing oriT from pSET152 [45]. A 163 bp NdeI-BglII region
of the resulting plasmid was further replaced by a 4365 bp fragment
containing the replication origin of pIJ101 and tsr, creating pJTU676.
A region of pJTU676, with the PermE* promoter, ribosomal binding
site (RBS), and NdeI site, was replaced with a corresponding frag-
ment from pIB139 [46] after digestion with EcoRI and HindIII. The
distance between the RBS and the start codon of the downstream
gene is 7 bp in the final construct, pJTU695, while that in pJTU676
is 23 bp.
DNA Sequencing and Analysis
DNA sequencing was performed using a set of five fragments di-
rectly isolated from cosmids 4G8 and 17F2 [15], or cloned onto
pBluescript SK(+) (Stratagene) or pSL301 (Invitrogen), which were
originally connected or overlapping to cover anw45 kb region withthe validamycin biosynthetic gene cluster (Figure 2A). pHZ2232
with the 1.0 kb BamHI fragment was directly sequenced with T3
and T7 primers. Sequencing analysis of the 21 kb ClaI fragment,
a 19.6 kb EcoRI fragment (pHZ2239), a 6.0 kb BamHI fragment
(pHZ2229), and 7.0 and 3.8 kb BamHI fragments (pJTU464) were
as described in [47].
Inactivation of valG
A 2.4 kb EcoRI-HindIII fragment flanking the left of the nt 112 of valG
and a 1.0 kb HindIII-EcoRI fragment flanking the right of the nt 918
of valG were coligated into EcoRI-digested pIJ2925 to generate
pJTU600. A HindIII fragment carrying the 1.4 kb aac(3)IV cassette
from pJTU472 was inserted into the HindIII site between the 2.4
and 1.0 kb fragments to generate pJTU607, from which a 4.8 kb BglII
fragment was excised for insertion into the BamHI-digested
pHZ1358 to construct a vector (pJTU609). pJTU609 was then used
for mediating gene replacement (Figure 4) to obtain a valG mutant
(LL-1). The mutation was confirmed by PCR amplification using for-
ward primer valG2-F (50- AGAGCCGATCTGGTGGTGAG-30) and re-
verse primer valG2-R (50-GGTGATGATTAGCCCTTCTCG-30).
Complementation of Mutant LL-1 with Cloned valG
PCR-amplified valG was cleaved as a 1.2 kb NdeI-EcoRI fragment
and cloned into pJTU695 digested with the same restriction en-
zymes. The new plasmid, pJTU612, was introduced from E. coli
into LL-1 through conjugation as previously described [15], and ex-
conjugants were selected with 25 mg/ml thiostrepton. Further confir-
mation was carried out through plasmid isolation from 2-day-old
mycelia, transformation into E. coli, and comparison between the
newly purified pJTU612 and the original one by restriction enzymes
digestions. An exconjugant having the correct plasmid, named
LL-101, was investigated through fermentation, bioassay, and
HPLC analysis, as previously described [15].
Targeted Disruption of valO
The valO gene was disrupted with ReDirect Technology. The aac
(3)IV and oriT cassette was amplified from the pIJ773 disruption cas-
sette [36] with the primers ValO-PCR-F (50-ATGTATAAGGTCGCA
CTTTTCGATCTGGACGGCACGTTAattccggggatccgtcgacc-30) and
ValO-PCR-R (50-TCACGTGACGTCGTGATTCGAATCGGAGGGAGG
AACGATtgtaggctggagctgcttc-30) (pIJ773 homologous sequence is
in lowercase letters). The resulting PCR product was used to replace
valO first in pJTU714, a pHZ1358-derived plasmid carrying the 7.0 kb
BamHI fragment containing valO, and then in strain 5008, as previ-
ously described [15]. Allelic replacement of valO in the ZYR-5 mutant
was confirmed by PCR amplification with the primers of ValO-Det-F
(50-CGACGACCCTCAACCTC-30) and ValO-Det-R (50-CTGGCATCA
AGCGACAC-30). Fermentation of ZYR-5 and activity comparison be-
tween the wild-type and ZYR-5 through bioassay and HPLC were
performed.
Cloning and Heterologous Overexpression of Recombinant
His6-Tagged ValG
The valG gene was amplified by PCR with Platinum Pfx DNA poly-
merase (Invitrogen) with the cosmid 3G8 as template and primers
ValGF3 (50-GAAGATCTGCATATGCCCGGTGCGACATCCCATG-30;
engineered BglII and NdeI sites are in italics) and ValGR2 (50-GGA
ATTCTCAGTCACCGCGAAGAGACGGCTCG-30; engineered EcoRI
site is in italics). The PCR amplification was done in a thermocycler
(Eppendorf, Mastercycler gradient) under the following conditions:
33 cycles of 90 s at 95ºC, 45 s at 60ºC, and 45 s at 72ºC. The PCR
products were digested with BglII and EcoRI, and subsequently
ligated into BamHI/EcoRI-digested pRSET-B. The constructs were
transformed into E. coli XL-1 Blue and plated on LB agar plates
containing 100 mg/ml ampicillin. The plasmid DNA was isolated
and introduced by heat-pulse transformation into E. coli BL21
Gold(DE3)/pLysS (Stratagene), which was then plated onto LB
agar plates containing 100 mg/ml ampicillin and 25 mg/ml chloram-
phenicol. The transformants were grown in 20 ml LB medium con-
taining ampicillin and chloramphenicol at 37ºC to an OD600 of 0.6.
IPTG was added to a final concentration of 0.2 mM, and the incuba-
tion was continued at 28ºC for 24 hr. The cells were harvested by
centrifugation at 3500 rpm for 15 min and stored frozen at 280ºC
until further use.
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of His6-Tagged ValG
Cells were thawed and resuspended in disruption buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole [pH 8.0]). The suspension
was sonicated three times for 25 s each, and cell debris was re-
moved by centrifugation at 10,000 rpm for 10 min. The protein solu-
tion was applied to a BD TALON spin column (BD Biosciences) and
centrifuged at 500 rpm for 2 min. The column was washed with
washing buffer (twice with 50 mM NaH2PO4, 300 mM NaCl [pH
8.0], and once with 50 mM NaH2PO4, 300 mM NaCl, 100 mM imidaz-
ole [pH 8.0]). The His6-tagged protein was eluted with elution buffer
(50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole [pH 8.0]) and
dialyzed for 24 hr against 1 liter of dialysis buffer (25 mM Tris-HCl
[pH 7.6], 10 mM MgCl2, 20 mM NH4Cl, and 0.5 mM DTT). Protein con-
centration was measured by the Bradford protein microassay with
bovine serum albumin as standard.
Enzyme Assay
The enzyme assay was carried out at 30ºC for 3–12 hr in a 100 ml vol-
ume of 25 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 20 mM NH4Cl, 15 mM
NDP-glucose, 10 mM validoxylamine A, and 50 ml of protein solution
(2.4 mg/ml protein). The reaction progress was monitored by TLC
analysis. For a scale-up experiment, 3.35 mg of validoxylamine A
was used. The reaction mixture was applied to a Microcon YM-10
(Amicon) spin column. The flow through was subjected to a cat-
ion-exchange (Dowex 50Wx8-200 [H+]) chromatography column.
The column was washed with 20 ml of water, and the reaction prod-
uct was eluted with 0.5 M aqueous NH4OH. Fractions containing the
desired product were pooled and lyophilized to give 4.1 mg of VAL-A
as a white powder.
Heterologous Production of Validoxylamine A and VAL-A
The valABC operon was first cloned downstream of the PermE* pro-
moter by inserting a 623 bp NdeI-FspI DNA fragment of valA and
a 3280 bp FspI-BamHI fragment from pHZ2229 into pSL301 di-
gested with NdeI and BamHI. Then, a 3964 bp NdeI-EcoRI fragment
containing the complete valABC was cleaved from the resulting
plasmid, pJTU755, and ligated into pIB139 digested with the corre-
sponding enzymes, generating pJTU756. Subsequently, a 5611 bp
EcoRI fragment, containing valKLMN from cosmid 17F2, was in-
serted into EcoRI-digested pJTU756. Clones with valABCKLMN
transcribed in the same orientation were selected and named
pJTU757.
Plasmid pJTU757 was integrated into the chromosome of S. livid-
ans 1326 by protoplast transformation and selection with apramycin
to create a recombinant XH-6. Introduction of pJTU612 carrying
valG into XH-6 by conjugation resulted in another recombinant
XH-9, which was selected with thiostrepton and apramycin. Fermen-
tation and bioassay analysis of XH-6 and XH-9 were done as previ-
ously described [15]. Tandem MS analysis was performed with fer-
mentation broth extracted once with chloroform through directed
injection on an Agilent 1100 series LC/MSD Trap system. The iontrap
mass spectrometer was operated with the electrospray ionization
source in the positive-ion mode. Drying gas flow was 10 liters/min,
and nebulizer pressure was 50 psi. Drying gas temperature was
325ºC. The fragmentation amplitude was varied between 1.0 and
1.8 V.
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